VISTA and PD-L1 synergistically predict poor prognosis in patients with extranodal natural killer/T-cell lymphoma

Although PD-1/PD-L1 blockade therapy confers salutary effects across cancer types, their efficacy in Extranodal Natural killer/T-cell lymphoma (ENKTCL) patients is limited and unpredictable. Here, we comprehensively evaluated the expression profile of a panel of immune-regulatory makers to identify...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncoimmunology
Autors principals: He, Hai-Xia, Gao, Yan, Fu, Jian-Chang, Zhou, Qiang-Hua, Wang, Xiao-Xiao, Bai, Bing, Li, Peng-Fei, Huang, Cheng, Rong, Qi-Xiang, Ping, Li-Qin, He, Yan-Xia, Mao, Jia-Ying, Chen, Xu, Huang, Hui-Qiang
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2021
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8032243/
https://ncbi.nlm.nih.gov/pubmed/33889438
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2021.1907059
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars